newsfilter
← Latest News
GlobeNewswire·

Entrada Therapeutics Reports Third Quarter 2026 Financial Results

-- All ELEVATE-44-201 Cohort 1 participants have completed open-label dosing, with data expected to be received by year-end 2026 -- -- Company on track to report ELEVATE-44-201 Cohort 2 data in Q1 2027 – --